Growing Up as a Childhood Cancer Survivor

Ask your treating center for a written treatment summary. At the least it should name your diagnosis and the dates. It should list the protocol. It should name every chemotherapy drug and its cumulative dose, the total given across the whole course. Anthracyclines matter most here, in mg/m2. It should also list radiation fields and total dose, surgeries, whether you had a stem cell transplant, and any major complications.

You will need this in your thirties. By then the pediatric hospital may have reorganized. Records may be gone. A new doctor will ask a question nobody else can answer. Keep a paper copy. Keep a photo on your phone. Give a copy to your primary care doctor. Without it, follow-up comes down to guessing.

The Children's Oncology Group (COG) Long-Term Follow-Up Guidelines set out screening advice. They cover people treated for cancer as children, teenagers or young adults. They are risk-based. They are sorted by exposure, not by diagnosis. What you were given decides what gets checked, and how often. They are free to read, and updated periodically. They are written for clinicians. But they come with plain-language handouts called Health Links, on heart health, fertility, hearing and second cancers. The Passport for Care tool can also build a personal schedule from your treatment history.

If you know your exposures, you can look up your own screening schedule. If you do not, that is the first problem to solve.

This is a map of what gets watched, not a forecast of what will happen.

Heart. Some drugs raise the risk of cardiomyopathy, a weakened heart muscle. These are the anthracyclines: doxorubicin, daunorubicin, idarubicin and epirubicin. Mitoxantrone and chest radiation do the same. Heart disease also shows up at a younger age in childhood cancer survivors. The usual check is echocardiography, an ultrasound scan of the heart. How often depends on cumulative dose and radiation exposure.

Fertility and hormones. Alkylating agents can reduce fertility. They include cyclophosphamide, ifosfamide, busulfan and melphalan. So can radiation to the pelvis, testes or whole body. They can also cause premature ovarian insufficiency, meaning ovaries that stop early, or low testosterone. Reduced fertility is not the same as infertility. Survivors who assumed they could not conceive do conceive. So contraception still matters.

Growth and endocrine. Cranial radiation means radiation to the head. It and total body irradiation can affect the hypothalamic-pituitary axis. That is the hormone control center in the brain. Harm there can cause growth hormone deficiency, early or late puberty, and thyroid problems. Neck radiation raises the risk of hypothyroidism, an underactive thyroid, and of thyroid nodules.

Thinking and learning. Some treatments are linked to changes in processing speed, attention and working memory. They include cranial radiation, brain surgery and total body irradiation. So does intrathecal methotrexate and cytarabine, given into the fluid around the spinal cord. These changes often surface later, as school or job demands rise. Formal neuropsychological testing turns "I am bad at this now" into documented accommodations.

Second cancers. Alkylating agents raise the risk of a second cancer. So do radiation and topoisomerase II inhibitors such as etoposide. The pattern follows the radiation field. Chest leads to breast. Neck leads to thyroid. Abdomen and pelvis lead to the gut and urinary tract. So chest radiation prompts breast screening from around age 25. Abdominal or pelvic radiation prompts colonoscopy, a camera test of the bowel, earlier than the general population schedule.

Also watched: hearing after platinum drugs. Kidney function after platinum and ifosfamide. Lung function after bleomycin and chest radiation. Bone density. Dental effects.

Between roughly 18 and 25, most survivors leave the pediatric system. This is where follow-up most often stops for good. Before you go, ask for four things. The treatment summary. A written screening schedule. A referral to a long-term follow-up clinic, or to an adult provider willing to use the guidelines. And the name of one person you can email with a question.

Contact medical records at the hospital that treated you. Ask for the oncology treatment summary and the radiation records by name. Ask your parents what they kept. Old calendars and insurance statements often carry drug names and dates. Contact a long-term follow-up clinic even if you were never a patient there.

Partial information is enough to start risk-based screening: the diagnosis, the rough years, and whether radiation was involved. Incomplete records are a reason to start now, not a reason to keep waiting.

Screening schedules cover what is expected. These are the things that should not wait for the next appointment.

• Call 911 or go to an emergency department if you get chest pain, or sudden numbness or weakness in the face, arm or leg, or a sudden severe headache with no cause you can name. NCI lists all of these as warning signs after treatments that affect the heart and blood vessels.
• Call your care team the same day if breathing gets hard when you lie flat, or your heartbeat turns fast, slow or irregular, or your feet, ankles, legs or abdomen swell. After anthracyclines or chest radiation these point at the heart muscle, and NCI is blunt that only a doctor can tell.
• Call your care team within a day or two if you find a lump in a breast or under an arm, or a bump or spot that has changed colour, size, shape or texture. Give it priority if it sits inside an old radiation field, since that is where second cancers tend to appear.

• NCI: Late Effects of Treatment for Childhood Cancer (PDQ), Patient Version
• NCI: Late Effects of Treatment for Childhood Cancer (PDQ), Health Professional Version
• NCI: Follow-Up Medical Care After Cancer Treatment
• NCI: Adolescents and Young Adults with Cancer